{
    "nct_id": "NCT00884507",
    "title": "A Dose-ranging, Randomized, Double-blind , Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2016-11-01",
    "description_brief": "This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, patients will be randomized to one of 4 treatments (placebo, or RO5313534 1mg, 5mg or 15mg po daily) with background therapy of donepezil (5mg or 10mg).The anticipated time on study treatment is 6 months, and the target sample size is 100-500 individuals.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "RO5313534",
        "MEM3454",
        "RG3487 (N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide hydrochloride)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests RO5313534 (also called MEM3454 / RG3487) as an add-on to donepezil with the primary outcome assessing cognitive function (ADAS\u2011Cog), which suggests the aim is to improve cognition rather than modify core AD pathology. \ue200cite\ue202turn2search2\ue202turn0search0\ue201",
        "Act: Web sources identify RO5313534 / MEM3454 / RG3487 as a small\u2011molecule agent \u2014 a selective nicotinic alpha7 (\u03b17nAChR) partial agonist with 5\u2011HT3 antagonist properties \u2014 with preclinical and early clinical data showing pro\u2011cognitive/attention effects. These characteristics and the trial design (dose\u2011ranging, short duration, cognitive endpoints, add\u2011on to donepezil) align it with symptomatic cognitive enhancement rather than a disease\u2011modifying biologic or small molecule targeting amyloid/tau. \ue200cite\ue202turn2search5\ue202turn2search7\ue201",
        "Reflect: Classification chosen = \"cognitive enhancer\" because (1) the compound is a small molecule targeting neurotransmitter receptors (\u03b17 nicotinic/5\u2011HT3) implicated in cognition (not amyloid or tau), (2) the trial's primary purpose and endpoints are cognitive (ADAS\u2011Cog) over 24 weeks as add\u2011on symptomatic therapy, and (3) sources indicate development was for cognitive symptoms. No evidence was found that RO5313534 is a biologic or a pathology\u2011targeting small molecule, so the other categories (disease\u2011targeted biologic / disease\u2011targeted small molecule / neuropsychiatric symptom improvement) do not fit. \ue200cite\ue202turn2search5\ue202turn2search2\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational compound RO5313534 (synonyms MEM3454, RG3487) is described and shown in the literature to be a small\u2011molecule selective nicotinic alpha7 (\u03b17 nAChR) partial agonist with additional 5\u2011HT3 antagonist properties, developed as a pro\u2011cognitive symptomatic agent (add\u2011on to donepezil) rather than a disease\u2011modifying anti\u2011amyloid/tau therapy. \ue200cite\ue202turn0search1\ue202turn0search3\ue201.",
        "Act: Based on the mechanism (direct modulation of neurotransmitter receptors \u2014 \u03b17 nicotinic and 5\u2011HT3), the CADRO category that matches best is D) Neurotransmitter Receptors. The trial design (dose\u2011ranging, cognitive endpoints, add\u2011on to donepezil) and preclinical/clinical reports support a symptomatic cognitive\u2011enhancer indication rather than targeting core AD pathology. \ue200cite\ue202turn0search3\ue202turn0search2\ue201.",
        "Reflect: Reassessed alternatives \u2014 the drug is not an anti\u2011amyloid or anti\u2011tau agent (so not A or B), not an anti\u2011inflammatory, metabolic, vascular, or epigenetic intervention, and it acts on classical neurotransmitter receptor targets, so D is the most specific CADRO fit. No sources indicate multi\u2011target disease modification or a non\u2011therapeutic diagnostic role, so 'R) Multi\u2011target' or 'T) Other' are not appropriate. \ue200cite\ue202turn0search1\ue202turn0search5\ue201.",
        "Web search / supporting results (key findings):",
        "- Alzforum entry summarizing RG3487 / RO5313534 / MEM3454 as a selective nicotinic \u03b17 receptor partial agonist (also 5\u2011HT3 antagonist), developed for AD cognition; development discontinued. \ue200cite\ue202turn0search1\ue201.",
        "- J Pharmacol Exp Ther / Psychopharmacology and related preclinical studies showing RG3487 is an \u03b17 partial agonist with 5\u2011HT3 antagonist activity and that it enhances cortical/hippocampal acetylcholine and dopamine \u2014 consistent with pro\u2011cognitive effects. \ue200cite\ue202turn0search3\ue202turn0search2\ue201.",
        "- Clinical reports: phase\u20112 programs (dose\u2011ranging add\u2011on studies to donepezil; investigated for cognition in AD and cognitive deficits in schizophrenia) describing symptomatic cognitive endpoints rather than disease\u2011modifying biomarkers. \ue200cite\ue202turn0search1\ue202turn0search5\ue201."
    ]
}